Harglim M 2 Forte Tablet SR is an oral antihyperglycemic medication formulated with a combination of Glimepiride 2mg and Metformin 1000mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. The sustained-release (SR) formulation ensures a gradual release of active ingredients, promoting stable plasma concentrations and improving patient compliance by reducing dosing frequency. Harglim M 2 Forte is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve optimal glycemic targets. It is essential to monitor blood glucose levels regularly during therapy to minimize the risk of hypoglycemia, particularly due to glimepiride’s insulinotropic effect. Caution is advised in patients with renal or hepatic impairment, as metformin is contraindicated in severe renal dysfunction due to the risk of lactic acidosis. This combination therapy should be used alongside lifestyle modifications, including diet and exercise, to optimize diabetes management and reduce the risk of long-term complications.